You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東寶生物(300239.SZ):骨膠原肽抑制腫瘤作用機制研究項目獲美髮明專利授權
格隆匯 10-21 11:51

格隆匯10月21日丨東寶生物(300239.SZ)宣佈,公司於近日收到美國專利授權通知,公司“骨膠原肽抑制腫瘤作用機制研究項目”在美國申請的發明專利已獲授權。該專利是一種具有抑制癌細胞增殖活性的膠原活性肽的製備方法,該活性肽具有抑制卵巢癌、前列腺癌細胞增殖作用。

專利名稱:《TECHNIQUES OF PREPARING COLLAGEN ACTIVE PEPTIDES》(膠原蛋白活性肽製備技術);專利號:US10,414,795B2;專利申請日:2017年3月15日;專利權人:中國科學院理化技術研究所;包頭東寶生物技術股份有限公司;Eric Hanxiang Sun(孫漢翔)。

上述專利的取得對公司佈局“醫藥健康”領域具有重要影響,是公司堅持技術創新取得的新突破,為公司後續開發新產品奠定堅實的基礎。公司後續將進一步加大研發力度,繼續研究膠原蛋白活性肽在腫瘤抑制領域的廣闊應用,並積極尋求合作伙伴共同開展研發、應用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account